logo
Sona Nanotech Announces Annual Options Grants

Sona Nanotech Announces Annual Options Grants

Globe and Mail01-05-2025
Halifax, Nova Scotia--(Newsfile Corp. - May 1, 2025) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 1,855,0000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Stock Option Plan.
Sona CEO, David Regan, commented, " These options include the annual compensation for our directors, who do not receive any cash compensation, and incentive options for our team providing for strong alignment with shareholder's interests. The Company continues to steward investor capital efficiently while making strong progress towards advancing Sona's novel THT cancer treatment towards the clinic. The entire Sona team is engaged and excited as we near the opportunity to showcase THT in a first-in-human clinical trial with initial read-outs expected this summer."
About Sona Nanotech Inc.
Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (42-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, and Sona's preclinical and clinical study plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PharmAla Issues Q3 Financial Statements
PharmAla Issues Q3 Financial Statements

Toronto Star

time2 days ago

  • Toronto Star

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ('PharmAla' or the 'Company') (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company's full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management's discussion and analysis can be accessed by visiting the Company's website at and its profile page on SEDAR+ at 'The re-opening of PharmAla's domestic Canadian distribution has allowed us to execute as much volume in Q2 and Q3 as we did in all of the last fiscal year. The creation of our Prescriber's Portal has also allowed us to build a much closer relationship with our doctor customers, which we believe will serve us well moving forward,' said Nick Kadysh, CEO, PharmAla Biotech. 'As we move into the last quarter of Fiscal '24-25, we are incredibly pleased that a large shipment of LaNeo MDMA has arrived at our US distribution partner for delivery to a considerable group of clinical trial customers, most previously announced. PharmAla is also pleased to announce the completion of a manufacturing run in Australia for our 40mg LaNeo Capsules. These capsules were jointly manufactured for both Cortexa's use within Australia and PharmAla's use worldwide, and our improved manufacturing process should yield operational benefits well into the future.'

Treatment.com AI Announces Non-Brokered Private Placement of up to C$3 million of Special Warrants and Units
Treatment.com AI Announces Non-Brokered Private Placement of up to C$3 million of Special Warrants and Units

Toronto Star

time2 days ago

  • Toronto Star

Treatment.com AI Announces Non-Brokered Private Placement of up to C$3 million of Special Warrants and Units

Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — AI Inc. (the 'Company' or 'Treatment') (CSE: TRUE; OTC: TREIF; 939: FRA) is pleased to announce that due to strong inbound interest from new and existing investors, it is undertaking a non-brokered private placement of up to C$3 million of a combination of special warrants of the Company (each, a 'Special Warrant') at a price of C$0.50 per Special Warrant and units of the Company (each, a 'Unit') at a price of C$0.50 per Unit ('Offering'). Each Unit shall consist of one common share of the Company (a 'Share') and one common share purchase warrant (each, a 'Warrant'). Each Warrant shall entitle the holder thereof to acquire one Share at a price of C$0.75 per Share for a period of 12 months following the date of issuance of the Warrants. Each Special Warrant will automatically convert, for no additional consideration, into one Unit on the date (the 'Conversion Date') that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the 'Prospectus Supplement') qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants, and (ii) 4 months and one day after the issue date of the Special Warrants. No Special Warrants may be exercised by the holder thereof prior to the Conversion Date.

ST. JAMES GOLD CORP. (TSX-V: LORD) ANNOUNCES REINSTATMENT OF TRADING, DEBT RESOLUTION, AND EXPIRED INVESTOR RELATIONS CONTRACT
ST. JAMES GOLD CORP. (TSX-V: LORD) ANNOUNCES REINSTATMENT OF TRADING, DEBT RESOLUTION, AND EXPIRED INVESTOR RELATIONS CONTRACT

Toronto Star

time2 days ago

  • Toronto Star

ST. JAMES GOLD CORP. (TSX-V: LORD) ANNOUNCES REINSTATMENT OF TRADING, DEBT RESOLUTION, AND EXPIRED INVESTOR RELATIONS CONTRACT

Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — St. James Gold Corp. (the 'Company' or 'St. James') (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) announced today that its common shares will be reinstated for trading on the TSX Venture Exchange (the 'Exchange') on or about July 29, 2025 as the TSX Venture Exchange has completed its review. The Company's financial statements for the period ended March 31, 2025 reflected a working capital deficiency $1,905,769. In order to resolve the deficiency and comply with the Exchange listing requirements, the Company has taken the following steps:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store